CAS: 32249-35-7; Methyl 3-Cyclopropyl-3-Oxopropanoate

相似化合物

251635-21-9 24922-02-9 630399-84-7

上下游产品

CAS号67-56-1 甲醇 | CAS号2033-24-1 丙二酸环(亚)异丙酯 | CAS号4023-34-1 环丙甲酰氯 | CAS号765-43-5 环丙甲基酮 | CAS号616-38-6 碳酸二甲酯 | CAS号38330-80-2 丙二酸单甲酯钾盐 | CAS号1759-53-1 环丙甲酸 | CAS号59533-64-1 2-cyclopropanec... | CAS号124-41-4 甲醇钠 | CAS号586966-54-3 匹伐他汀叔丁酯 | CAS号21573-09-1 4-氯-6-环丙基嘧啶-2-胺 | CAS号147526-32-7 匹伐他汀钙 | CAS号121659-86-7 2-环丙基-4-(4-氟苯基)... | CAS号121660-37-5 2-环丙基-4-(4-氟苯基)... | CAS号121660-11-5 2-环丙基-4-(4-氟苯基)... | CAS号147489-06-3 6-[[(1E)-2-环丙基-... | CAS号148901-69-3 (E)-7-[2-环丙基-4-... | CAS号148901-68-2 (E)-3-[2-环丙基-4-... | CAS号862695-75-8 6-氯-2-环丙基烟酸

5-(Cyclopropylhydroxymethylidene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione 以 乙醇 用作溶剂,化学反应 3.0H,反应生成3-环丙基-3-氧代丙酸甲酯
参考文献:在无金属催化剂,无外源氧化剂和无外源电解质的条件下电化学合成多功能氧化铵
标题:在无金属催化剂,无外源氧化剂和无外源电解质的条件下电化学合成多功能氧化铵
摘要:已经开发了2.5-取代的吡唑啉-5-酮与硫氰酸铵之间的电化学氧化交叉偶联反应,从而在金属催化剂,外源氧化剂和外源电解质-的作用下产生了一系列前所未有的交叉偶联产物.免费条件.值得注意的是,由于所得的交叉偶联产物几乎不溶于mecn,因此无需硅胶柱纯化即可提供纯产物.此外,制备的氧化铵是用于合成官能化吡唑衍生物的通用构建基.
Doi:10.1039/d1Cc00486G

专利信息

专利号:US-9751874-B2
优先权日:2014-12-17
标题:Hydroxy containing FXR (NR1H4) modulating compounds
发明人：GEGE CHRISTIAN; KINZEL OLAF; KREMOSER CLAUS; SCHMITT AARON C
权利人:GILEAD SCIENCES INC
摘要:The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

专利号:US-9861636-B2
优先权日:2014-04-29
标题 :Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors
发明人：HE WEI
权利人:HE WEI; ZHEJIANG DTRM BIOPHARMA CO LTD
摘要:Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.

专利号:US-2023295141-A1
优先权日:2022-03-17
标 题:Fxr small molecule agonist, the preparation and use thereof
发明人：ZHAO YISHUANG; ZHANG ZHENWEI; WU GUOHUI; YANG SHENGSHENG
权利人:CASCADE PHARMACEUTICALS INC
摘要:The present invention discloses an FXR (farnesoid X receptor) small molecule agonist, the structure of which is shown in formula I, and a preparation method thereof. In the formula, the definition of each substituent is as described in the specification and claims. The compound of the present invention has advantages, such as high FXR agonistic activity, convenience in synthesis, easy availability of raw materials, and can be used as a medicine for the treatment of FXR-related diseases.

专利号:US-2010010219-A1
优先权日:2006-12-07
标 题 :Method for producing pyrrolidine compound
发明人：HARADA KAZUHITO; ITO TAKASHI
权利人:JAPAN TOBACCO INC
摘要:Provided is a method capable of efficiently producing a compound having a superior HSD1 inhibitory action and a compound useful as a synthetic intermediate therefor, with superior achievability of asymmetric synthesis (i.e., superior selectivity), superior yield, superior safety and superior industrial workability at a low cost. n A method of producing a compound represented by the following formula [8]: n n n n n n n n n n or a salt thereof, or a solvate thereof, from a compound represented by the following formula [2]: n n n n n n n n n n or a reactive derivative thereof, or a salt thereof, or a solvate thereof.